Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.12%. A quarter ago, it was expected that this medical device maker would post earnings of $0.39 per share when it actually produced earnings of $0.41, delivering a surprise of 5.13%.Over the last four quart ...

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance Princeton, New Jersey, February 25, 2025 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Full-Year 2024 2024 Business Highlights "As I step into my role leading Integra, I am inspired by the strength of our portfolio, the dedication of our team, and the t ...

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per dil ...

Core Insights - GHO Capital has appointed Jan De Witte as Operating Partner to enhance its portfolio and support transatlantic deal origination [2][6] - Jan De Witte brings extensive experience in leading international growth and transformation in the healthcare and technology sectors [3][4] - GHO Capital aims to leverage Jan's expertise to identify high-growth potential businesses within the healthcare sector [7] Company Overview - GHO Capital Partners LLP is a specialist healthcare investment advisor based in London, focusing on high-growth healthcare opportunities [9] - The firm targets Pan-European and transatlantic internationalization to build market-leading businesses of strategic global value [9] - GHO Capital emphasizes improving healthcare delivery efficiency to enable better, faster, and more accessible healthcare [9] Leadership Background - Jan De Witte previously served as CEO of Integra LifeSciences, where he added $1 billion to the company's total addressable market through strategic acquisitions and innovation [3] - He has also held leadership positions at Barco N.V. and GE Healthcare, focusing on digital transformation and global market expansion [4] - Jan holds an M.B.A. from Harvard Business School and degrees in electromechanical engineering from KU Leuven, Belgium [5]

PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those pl ...

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to fin ...

New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledgePRINCETON, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of its global medical education platform Integra Institute. This new digital resource is designed to elevate Integra’s medical education offerings in surgical, neurologic, ENT and regenerative care​ by enhancing professiona ...

Core Viewpoint - Investors in the Medical - Instruments sector should consider Integra LifeSciences (IART) and Penumbra (PEN) as potential value opportunities, with IART appearing to be the superior option based on valuation metrics [1][7]. Valuation Metrics - Both IART and PEN have a Zacks Rank of 2 (Buy), indicating positive earnings outlooks due to recent revisions in earnings estimates [3]. - IART has a forward P/E ratio of 9.26, significantly lower than PEN's forward P/E of 62.66, suggesting IART may be undervalued [5]. - The PEG ratio for IART is 0.77, while PEN's PEG ratio is 1.77, indicating IART has a more favorable growth valuation [5]. - IART's P/B ratio is 1.18, compared to PEN's P/B of 8.41, further supporting IART's stronger valuation profile [6]. - These metrics contribute to IART receiving a Value grade of A, while PEN has a Value grade of C [6].

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...